TY - JOUR AU - Zhang, Wenchao AU - Yin, Mei AU - Li, Wei AU - Xu, Nana AU - Lu, Haining AU - Qin, Weidong AU - Han, Hui AU - Li, Chen AU - Wu, Dawei AU - Wang, Hao T1 - Acinetobacter baumannii among Patients Receiving Glucocorticoid Aerosol Therapy during Invasive Mechanical Ventilation, China T2 - Emerging Infectious Disease journal PY - 2022 VL - 28 IS - 12 SP - 2404 SN - 1080-6059 AB - Acinetobacter baumannii is a nosocomial pathogen associated with severe illness and death. Glucocorticoid aerosol is a common inhalation therapy in patients receiving invasive mechanical ventilation. We conducted a prospective cohort study to analyze the association between glucocorticoid aerosol therapy and A. baumannii isolation from ventilator patients in China. Of 497 enrolled patients, 262 (52.7%) received glucocorticoid aerosol, and A. baumannii was isolated from 159 (32.0%). Glucocorticoid aerosol therapy was an independent risk factor for A. baumannii isolation (hazard ratio 1.5, 95% CI 1.02–2.28; p = 0.038). Patients receiving glucocorticoid aerosol had a higher cumulative hazard for A. baumannii isolation and analysis showed that glucocorticoid aerosol therapy increased A. baumannii isolation in most subpopulations. Glucocorticoid aerosol was not a direct risk factor for 30-day mortality, but A. baumannii isolation was independently associated with 30-day mortality in ventilator patients. Physicians should consider potential A. baumannii infection when prescribing glucocorticoid aerosol therapy. KW - Acinetobacter baumannii KW - bacteria KW - antimicrobial resistance KW - aerosol inhalation KW - glucocorticoid KW - invasive mechanical ventilation KW - healthcare-associated infections KW - China DO - 10.3201/eid2812.220347 UR - https://wwwnc.cdc.gov/eid/article/28/12/22-0347_article ER - End of Reference